Nanobiotix News

12,495 +2,11% +0,258 €
15:40 Uhr Stuttgart | Mehr Kurse »
WKN: A1J7EB
ISIN: FR0011341205
Typ: Aktie

Nanobiotix News

15.11.17 Nanobiotix revenues for the 3rd quarter of 2017 Businesswire
13.11.17 Nanobiotix Presented New Clinical and Pre-​Clinical Data Confirming NBTXR3’s Significant Potential Role In Immuno-​Oncology at SITC Annual Meeting Businesswire
13.11.17 NANOBIOTIX presented new clinical and pre-​clinical data confirming NBTXR3's significant potential role in Immuno-​Oncology at SITC Annual Meeting GlobeNewswire
09.11.17 Nanobiotix Provides Update on the Global Development of Its Lead Product NBTXR3 Businesswire
09.11.17 NANOBIOTIX provides update on the global development of its lead product NBTXR3 GlobeNewswire
31.10.17 NANOBIOTIX Successfully Completes Approximately Eur 27.2 Million Placement of New Shares Businesswire
30.10.17 Nanobiotix Launches Capital Increase by Means of an Accelerated Bookbuild Offering Businesswire
23.10.17 Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma Businesswire
23.10.17 NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma GlobeNewswire
28.09.17 Nanobiotix Plans to Conduct Its First Clinical Trial with NBTXR3 in Combination with Immune Checkpoint Inhibitors in the U.S. Businesswire
28.09.17 NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. GlobeNewswire
31.08.17 NANOBIOTIX half year results for the six months ended 30 June 2017 GlobeNewswire
15.06.17 NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop GlobeNewswire
05.06.17 NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting GlobeNewswire
18.05.17 NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-​Oncology GlobeNewswire
28.04.17 NANOBIOTIX : 2016 Annual Results GlobeNewswire
04.04.17 NANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-​Oncology ; new clinical data to be presented at ASCO GlobeNewswire
23.03.17 NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma GlobeNewswire
07.03.17 NANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017 GlobeNewswire
07.02.17 NANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer GlobeNewswire
31.01.17 NANOBIOTIX : 2016 review and 2017 anticipated milestones GlobeNewswire
14.12.16 NANOBIOTIX reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial GlobeNewswire
28.11.16 NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3 GlobeNewswire
14.11.16 NANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
20.10.16 Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia GlobeNewswire
03.10.16 NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations GlobeNewswire
19.09.16 Bpifrance grants Nanobiotix a 2M€ interest-​free loan to support final development stage of lead product, NBTXR3 GlobeNewswire
13.09.16 Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe GlobeNewswire
06.07.16 Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer GlobeNewswire
31.05.16 Nanobiotix establishes promising preclinical proof-​of-concept in Immuno Oncology GlobeNewswire
29.04.16 Nanobiotix: 2015 Annual Results GlobeNewswire
04.01.16 NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer GlobeNewswire
13.11.15 Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened GlobeNewswire
01.07.15 NANOBIOTIX :starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 GlobeNewswire
10.06.15 NANOBIOTIX :reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 GlobeNewswire
14.04.15 NANOBIOTIX : 2014 ANNUAL RESULTS GlobeNewswire
19.02.15 Professor Robert Langer joins Nanobiotix as Scientific Advisor GlobeNewswire
16.10.14 Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe GlobeNewswire
08.10.14 PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-​Pacific GlobeNewswire
02.06.14 Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO GlobeNewswire
10.02.14 NANOBIOTIX :sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch in 2016 GlobeNewswire
06.12.13 NANOBIOTIX :strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar GlobeNewswire
23.09.13 NANOBIOTIX strengthens its management team GlobeNewswire
30.08.13 NANOBIOTIX : Half Year Results for the period ended 30 June 2013 GlobeNewswire
03.07.13 Nanobiotix announces ¤2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication GlobeNewswire
26.06.13 Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development GlobeNewswire
13.06.13 Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3 GlobeNewswire
03.06.13 Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-​Of-Concept in Phase I Trial of Soft Tissue Sarcoma GlobeNewswire